JOHN JOHNSON - 07 Jun 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
07 Jun 2023
Net transactions value
$0
Form type
4
Filing time
07 Jun 2023, 16:59:34 UTC
Previous filing
05 Jun 2023
Next filing
07 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +42,500 +8.6% $0.000000 535,812 07 Jun 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders.